)
Stepan Company (SCL) investor relations material
Stepan Company Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Adjusted EBITDA rose 18% to $66.3 million on 7% organic volume growth, margin recovery and Project Catalyst savings; all three segments delivered higher adjusted EBITDA YoY
Q3 net sales increased 17% to $692.2 million; adjusted net income rose 98% to $21.7 million and adjusted diluted EPS increased to $0.94 from $0.48
Net leverage improved to 2.4x, with positive free cash flow and continued balance-sheet deleveraging as priorities
Financial highlights
Reported Q3 net income was $17.8 million, or $0.78 per diluted share, versus $10.8 million, or $0.47; results included a $5.6 million pre-tax restructuring charge
Q3 gross profit was $87.6 million versus $71.0 million; operating income increased 19% to $26.0 million
9M net sales rose 11% to $1.981 billion; a $76.1 million restructuring charge contributed to a reported net loss of $0.7 million, while adjusted net income was $59.1 million
9M adjusted EBITDA increased 15% to $190.3 million; reported operating income fell 80% to $13.5 million
Outlook and guidance
2026 outlook calls for adjusted EBITDA growth, positive free cash flow and continued deleveraging
Project Catalyst savings are expected to exceed the $60 million 2026 target, with management indicating a $66 million–$70 million range; Q3 savings run rate was $23 million
Project Catalyst savings are expected to average above $25 million per quarter in 2027, with a faster contribution in H2 as Pasadena production ramps
2026 capital expenditures are forecast at $100 million–$105 million; scheduled debt repayments are $59 million, net interest $24 million–$25 million, and the effective tax rate 23%–25%
Q4 volume growth is expected to be below Q2's 6% and Q3's 7%; full-year organic volume growth through 9M was 4%
- FY destocking cut earnings, but Q4 volume growth and 2024 EBITDA recovery are expected.SCL
Q4 2023 - Margin recovery accelerates with 45% EBITDA growth and strategic shift to higher-margin segments.SCL
17th Annual Midwest IDEAS Conference - Q2 2026 adjusted EBITDA rose 45% to $74.4M on strong segment growth and margin recovery.SCL
Q2 2026 - Net loss of $41.4M driven by restructuring, with adjusted EBITDA down 14% and sales up 2%.SCL
Q1 2026 - 2025 results highlight diversified growth, operational excellence, and a robust innovation pipeline.SCL
Investor presentation - Proxy covers director elections, pay practices, auditor ratification, and strong governance.SCL
Proxy filing - Adjusted EBITDA grew 6% in 2025; Project Catalyst targets $100M in savings, with H2 2026 recovery expected.SCL
Q4 2025 - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 2024 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 2024
)
)
)
)
)
)
)
)